Hey. transcribing it from spotify was not easy. at least

New Post Public Reply Private Reply Replies (0) Message Board
twinter11 SporadicE #165291
111
Hey. transcribing it from spotify was not easy. at least for me.
it dropped out some middle sections.
i went and grabbed it.

Katie Barber (Host): Yeah, absolutely. And I don't see as many of those entry-level positions around now as we used to, which is a real shame. And I agree with you, I think it's definitely hard now for a lot of PhD graduates to find that move. But I love that you said you kind of stood in line and waited—really outside the comfort zone—but it sounded like you kind of gave yourself a little bit of confidence you needed to go ahead and do it. And I'd love to understand how your career kind of took off from there. So how long were you with Rho and then how did you progress on through regulatory affairs from there?

Navigating Leadership Roles from CROs to Biotech

Dr. Lauren Wilcoxen: So, you know, it's something I still tell people and I tell my kids, right, is you got to get comfortable with being uncomfortable. And so I would say even in my career early on at Rho, I would volunteer a lot, right? I would volunteer for opportunities and projects and positions and roles that maybe I wasn't fully qualified for, frankly, right? But I felt like I had enough so that I needed enough experience and then to at least try and then ask questions along the way and learn, right? And that was really how I sort of continued to grow pretty rapidly at Rho from a leadership perspective—worked my way from doing some regulatory writing and quality control and review of documents, very quickly progressing to being a leader of both regulatory submissions and regulatory projects, as well as clinical trials.
That taught me a ton, right? I was able to learn both what it's like to manage a clinical trial on a day-to-day basis—you have to be extremely detail-oriented and manage all of these different pieces—all the way up through how to understand how to build and execute on a regulatory strategy for a marketing application. And so that was incredibly valuable. I did work my way up. I got promoted a couple times at Rho and then it was interesting: Rho had, before I joined, disbanded departments a couple of years before I joined to have more of a flat organization, more of a project-based learning environment, leadership environment. And it was quite helpful in certain aspects because depending on the team and the project I was on, sometimes I would be leading the project, sometimes I'd be an individual contributor on the project, and you learn a lot in that way. However, I also felt like I had sort of gotten to a ceiling there where I wasn't really sure, other than continuing to take on more projects, what kind of trajectory I would have there as a leader.

  And so I had been contacted by a recruiter for a position that was certainly more structured—more of the kind of traditional leadership structure environment that you would expect with departments and heads of departments. And it was a position to basically develop a department for US regulatory for PSI CRO, which is a global CRO. At this time Rho was really predominantly US-based, whereas PSI was global, was headquartered in Europe, and they had grown organically over time to be a global CRO. And it was also an opportunity to lead a department, to build a department, to build a team and processes and all of these things that I thought would help me grow. So I took that opportunity. About a week after I joined, they said, "Well, will you take over leadership of Canada regulatory as well?" Again, it's one of those themes where you get opportunities and you can either shy away or you can say, "Yeah, sure, I'll try that, and maybe I'll fail and maybe I won't, but either way, I'll learn from it." So that was that opportunity then to grow and lead a department and grow a team and build processes and SOPs and work with my colleagues cross-functionally all over the world. It was an incredible environment to grow and learn from.

And then again, I was sort of thinking about at that point: okay, what's next? Again, I was contacted by a recruiter for a position which was also very different and interesting in a lot of ways—working at Optum, part of UnitedHealth Group, to build a clinical research group there. That was a big company, much bigger than Rho and PSI which were more small-to-mid-sized CROs, and sort of almost building a mini-CRO within a healthcare company, right? So again, quite an interesting experience—building processes, building a team. I joined as Head of Regulatory and then was asked to take over program management and clinical as well. While I was there, I also helped to lead software development for a software that helped to identify patients for clinical trials based on electronic health record data.

  So again, all of these interesting things I was learning and developing and experiencing, and then I utilized that experience to say: okay, I've done things on sort of the CRO side, the healthcare side—I really want to be on the sponsor side now. I really want to go and be part of the biotech environment and feel what it's like to own the products that I'm helping to bring to market. And so that drew me to an opportunity at Istari Oncology, which was a clinical-stage biotech focusing on immuno-oncology therapeutics. And so that was very interesting. The lead asset was a virus-based platform, which as a virologist and immunologist by training, that was interesting to me. And the program was really focused on glioblastoma and had been in the clinic for about a decade at the time. And they needed industry professionals to come in and figure out: okay, how do we take this program forward to hopefully get approval and commercialization?

  And so that's where I came in again, to sort of build a regulatory department, to build processes, but also to really work through some of the early clinical data and develop that glioblastoma program, but also expand the program into other indications and try to build out that platform more. I came in and I grew that program across multiple solid tumors, multiple INDs. We had multiple meetings with FDA and progressed that forward. Unfortunately, this was sort of when I joined the company—it was during the COVID pandemic, early on during the pandemic... ...And again, it's an opportunity that I have really relished. I've grown a lot in the small environments, both from successes and sort of stepping stones through failures. And yeah, it's been very rewarding.

Essential Mindset for Thriving in Startup Biotech

Katie Barber (Host): What sort of advice would you have for someone who's looking to get into startup biotech for the first time? Particularly when it comes to mindset, right? It sounds like you and your team have that type of mindset. Like what advice would you give someone? What do they need to be prepared for?

  Dr. Lauren Wilcoxen: Yeah, be prepared for the unknown, right? The ambiguity, the failures, the ups and downs. There's going to be periods of time where you're going to be incredibly busy and stressed. And then there's going to be other times where maybe there's some reprieve, right? And everything in between.
I think it's important to have goals when you're in a small company. Maybe you have an end goal of commercialization and commercializing yourself. Maybe your end goal is to be acquired. Maybe there's different kinds of goals that you have as a small company. Being comfortable with that as well—trying to be on the same page with what those goals are in leadership early on—is also important.

  I think something that helped me, and I encourage folks that I talk to earlier in their careers or who are trying to make a career transition, is: take advantage of LinkedIn, take advantage of local networking organizations or local professional organizations. There's a local one here in North Carolina for regulatory affairs that helped me network, helped me meet new people, exposed me to different types of positions and different areas in the industry that I hadn't really thought about before. And I think that can be incredibly helpful if you are looking to enter into that phase, or maybe you're at a big company and you're like, "Well, what's it like as a startup?"

  The best way is to ask questions. Very early in my career I was very uncomfortable with that—was not the person to go to those environments and conferences and networking events and really want to network. I would always think, "I don't know if I should talk to this person, and what do I say? I don't want to interrupt this group, and how do I start a conversation? This is so awkward, right?" And you just have to sort of be comfortable with being uncomfortable—go ahead and do it anyway and have the conversation. And they're probably feeling something similar to where you are, or maybe they did early on in their career and they understand, right? So at least sort of rip the band-aid off and try and have the conversation, and you never know where it'll lead.

So many of those conversations have led to friendships, have led to mentorships, have led to professional connections who maybe were one or two degrees removed from somebody else who I learned from or benefited from professionally. So I think again, be comfortable with being uncomfortable. Ask questions, talk to people in the position or in a company like one that you would like to work at to really try to peel back those layers—understand what you're getting into and understand the level of risk. If you're risk-intolerant, a startup environment is probably not for you, and that's okay, right? We all have different values. We all have different tolerances for risk, and so I think trying to understand that about yourself is really helpful, and some of these conversations can help with that as well.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 145

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 41

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 46

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 91

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 95

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 125

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 117

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 73

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
MERSCO’s Holiday Push Tests Backyard Play Demand in 2026

Updated Category News Views 22

A trampoline sale is not exactly a macroeconomic bellwether, but it does expose a useful little corner of holiday spending: parents buying big, awkward, discretionary stuff that has to earn its space in the yard. MERSCO is joining Amazon’s Black Friday and Cyber Monday window from November 19 through November 30, 2026, with discounts reaching 38% on selected products....

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 38

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
/section>

Top 5 Most Recently Viewed Articles

Unveiling Groundbreaking Research on Cenobamate at AES 2025

Updated Category News Views 163

Exciting New Developments in Epilepsy Treatment SK Life Science, Inc., a leading player in central nervous system (CNS) disorder treatments and a subsidiary of SK Biopharmaceuticals Co., Ltd., is ready to unveil ten posters featuring new research on cenobamate at the upcoming American Epilepsy Society (AES) Annual Meeting. This prestigious event will take place in...

Continue Reading
Teck Resources Unveils Strong First Quarter Earnings for 2025

Updated Category News Views 384

Teck Resources Limited Reports Impressive First Quarter Results Teck Resources Limited (NYSE: TECK, TSX: TECK.A, TSX: TECK.B) has announced its unaudited financial results for the first quarter of 2025, showcasing significant improvements over previous years. This marks a period of enhanced profitability driven by favorable market conditions. Financial Performance...

Continue Reading
Understanding Your Rights in the Symbotic Class Action

Updated Category News Views 155

Taking Action: Your Rights as an Investor in Symbotic Inc. Investors of Symbotic Inc. should be aware of a class action lawsuit initiated on their behalf. The law firm Kirby McInerney LLP is advocating for those who acquired Symbotic securities during the noted class period. This comes as a crucial reminder for shareholders to stay informed and consider their rights in...

Continue Reading
Scott Kelly Joins Worthington Steel Board, Boosting Strategy

Updated Category News Views 431

Scott Kelly Named to Worthington Steel Board Worthington Steel, Inc. (NYSE:WS), a prominent player in the metals processing industry, has officially welcomed Scott Kelly to its board of directors. This strategic appointment comes at a significant time as the company navigates its market challenges, including a recent 10% dip in stock price. Despite this, Worthington...

Continue Reading
Treasury Securities Agreements: A New Era for Primary Dealers

Updated Category News Views 232

Understanding the Latest Developments in Treasury Securities In a significant move to fortify the issuance and market making in Treasury securities, the Government Debt Management, on behalf of the Treasury, has signed crucial agreements with primary dealers. This initiative aims to ensure the Treasury’s uninterrupted access to financing while enhancing price formation...

Continue Reading